Trial Profile
A Randomized Placebo-Controlled Trial of the Efficacy of Preventive Dosage of Fondaparinux Sodium Versus Placebo for the Prevention of Venous Thromboembolism in Patients Undergoing Coronary Artery Bypass Graft Surgery (CABG).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2022
Price :
$35
*
At a glance
- Drugs Fondaparinux sodium (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism; Venous thromboembolism
- Focus Therapeutic Use
- 29 Dec 2015 As per an article published in the American Heart Journal, this trial has been terminated early because of the relocation of the principal investigator to a new institution.
- 29 Dec 2015 Status changed from active, no longer recruiting to discontinued, as per an article published in the American Heart Journal
- 29 Dec 2015 Results published in the American Heart Journal